Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study

详细信息    查看全文

• 作者：Antonio Bruno ; ^{antonio.bruno@unime.it} ; Gianluca Pandolfo ; Manuela Crucitti ; Antonino Maisano ; Rocco A. Zoccali ; Maria Rosaria Anna Muscatello
• 关键词：Bergamot polyphenolic fraction ; Second-generation antipsychotics ; Weight gain ; Hyperlipemia ; Hyperglycemia ; Metabolic syndrome
• 刊名：The Journal of Nutritional Biochemistry
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：40
• 期：Complete
• 页码：32-35
• 全文大小：197 K
• 卷排序：40

文摘

Second-generation antipsychotics (SGAs) are notoriously associated with a marked increase in body weight and with a wide range of metabolic adverse effects, and their chronic use is related with an increased risk for the development of metabolic syndrome (MS). Different adjunctive treatments have been proposed to reduce SGAs-induced weight gain and/or metabolic abnormalities with inconsistent or too limited evidence to support their regular clinical use, thus suggesting the need to find new possible treatments. Bergamot polyphenolic fraction (BPF) has been proven effective in patients with MS, as demonstrated by a concomitant improvement in lipemic and glycemic profiles. The present study was aimed to explore the efficacy and safety of BPF treatment on metabolic parameters in a sample of subjects receiving atypical antipsychotics. Fifteen outpatients treated with SGAs assumed BPF at the oral daily dose of 1000 mg/day for 30 days. Fasting levels of glucose, glycated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides were determined. BPF administration resulted in a statistically significant reduction of body weight (P=.004) and in a trend for body mass index decrease (P=.005). No significant differences in other and metabolic parameters were observed. Our findings suggest that BPF, at the daily dose of 1000 mg for 30 days, could be an effective and safe agent to prevent weight gain associated with atypical antipsychotic use. However, further clinical trials with adequately powered and well-designed methodology are needed to better explore the BPF effectiveness on the SGAs-induced weight gain and metabolic side effects.